SHENZHEN, China, June 24, 2026 /PRNewswire/ — From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhibition. The company was also invited to attend the CPHI Award ceremony and received the R&D Innovation Award for its achievements in innovation and international development.Multi-field Product Coverage and Recognition with Innovation AwardsIts exhibited products spanned the fields of oncology, autoimmunity, and metabolic diseases. Blockbuster drugs such as albumin-bound paclitaxel, bevacizumab, infliximab, enzalutamide, aflibercept, liraglutide,…